0001558370-21-012233 | 6-K | XBRL Viewer

Document and Entity Information	6 Months Ended
Document and Entity Information	Jun. 30, 2021
Document Information [Line Items]
Entity Registrant Name	Centogene N.V.
Entity Central Index Key	0001757097
Document Type	6-K
Document Period End Date	Jun. 30, 2021
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q2

Unaudited interim condensed consolidated statements of comprehensive loss - EUR (€) € in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Unaudited interim condensed consolidated statements of comprehensive loss
Revenue	€ 51,871	€ 9,719	€ 116,831	€ 21,824
Cost of sales	43,760	6,815	95,707	13,833
Gross profit	8,111	2,904	21,124	7,991
Research and development expenses	4,053	3,119	8,388	5,810
General administrative expenses	10,494	7,767	22,090	15,665
Selling expenses	1,942	2,386	3,891	4,712
Impairment of financial assets	580	500	675	1,674
Other operating income	1,276	801	1,642	1,746
Other operating expenses	2	37	36	138
Operating loss	(7,684)	(10,104)	(12,314)	(18,262)
Interest and similar income		13		13
Interest and similar expense	212	269	471	718
Financial costs, net	(212)	(256)	(471)	(705)
Loss before taxes	(7,896)	(10,360)	(12,785)	(18,967)
Income tax expenses	124		124	129
Loss for the period	(8,020)	(10,360)	(12,909)	(19,096)
Other comprehensive income/ (loss), all attributable to equity holders of the parent	(191)	(6)	(70)	70
Total comprehensive loss	(8,211)	(10,366)	(12,979)	(19,026)
Attributable to:
Equity holders of the parent	(8,222)	(10,364)	(13,025)	(18,963)
Non-controlling interests	11	(2)	46	(63)
Total comprehensive loss	€ (8,211)	€ (10,366)	€ (12,979)	€ (19,026)
Loss per share - Basic and diluted (in EUR)	€ (0.37)	€ (0.52)	€ (0.58)	€ (0.95)

Unaudited interim condensed consolidated statements of financial position - EUR (€) € in Thousands	Jun. 30, 2021	Dec. 31, 2020
Non-current assets
Intangible assets	€ 12,179	€ 12,407
Property, plant and equipment	16,411	16,590
Right-of-use assets	20,558	22,120
Other assets	3,023	1,967
Non-current assets	52,171	53,084
Current assets
Inventories	9,281	11,405
Trade receivables and contract assets	18,490	29,199
Other assets	6,064	8,286
Cash and cash equivalents	34,780	48,156
Current assets	68,615	97,046
Assets	120,786	150,130
Equity
Issued capital	2,693	2,654
Capital reserve	130,153	125,916
Retained earnings and other reserves	(75,913)	(62,888)
Non-controlling interests	141	95
Equity	57,074	65,777
Non-current liabilities
Non-current loans	200	401
Lease liabilities	16,209	17,677
Deferred tax liabilities	246	207
Government grants	8,640	8,950
Non-current liabilities	25,295	27,235
Current liabilities
Government grants	1,352	1,342
Current loans	3,883	2,492
Lease liabilities	3,299	3,528
Trade payables	14,014	31,736
Liabilities from income taxes	143	58
Other liabilities	15,726	17,962
Current liabilities	38,417	57,118
Equity and liabilities	€ 120,786	€ 150,130

Unaudited interim condensed consolidated statements of cash flows - EUR (€) € in Thousands	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Operating activities
Loss before taxes	€ (12,785)	€ (18,967)
Adjustments to reconcile loss to cash flow from operating activities
Amortization and depreciation	6,670	4,432
Interest income		(13)
Interest expense	471	718
Expected credit loss allowances on trade receivables and contract assets	675	1,674
Share-based payment expenses	4,276	1,393
Tax expense	124	129
Other non-cash items	126	(686)
Changes in operating assets and liabilities
Inventories	2,124	(6,252)
Trade receivables and contract assets	10,034	(64)
Other assets	328	269
Trade payables	(17,722)	274
Other liabilities	(2,151)	2,457
Cash flow used in operating activities	(7,830)	(14,636)
Investing activities
Cash paid for investments in intangible assets	(2,089)	(3,965)
Cash paid for investments in property, plant and equipment	(2,696)	(3,072)
Grants received for investment in property, plant and equipment	0	390
Interest received		13
Cash flow used in investing activities	(4,785)	(6,634)
Financing activities
Cash paid for acquisition of non-wholly owned subsidiary		(75)
Cash received from loans	1,769	928
Cash repayments of loans	(185)	(1,260)
Cash repayments of lease liabilities	(2,263)	(1,619)
Interest paid	(82)	(399)
Cash flow from used in financing activities	(761)	(2,425)
Changes in cash and cash equivalents	(13,376)	(23,695)
Cash and cash equivalents at the beginning of the period	48,156	41,095
Cash and cash equivalents at the end of the period	€ 34,780	€ 17,400

Unaudited interim condensed consolidated statements of changes in equity - EUR (€) € in Thousands	Total	Issued capital	Capital reserve	Currency translation reserve	Retained earnings	Non-controlling interests	Total
Balance at beginning of the period at Dec. 31, 2019	€ 59,860	€ 2,383	€ 98,099		€ (40,622)	€ (938)	€ 58,922
Loss for the period	(19,033)				(19,033)	(63)	(19,096)
Other comprehensive loss	70			€ 70			70
Total comprehensive loss	(18,963)			70	(19,033)	(63)	(19,026)
Share-based payments	1,393		1,393				1,393
Disposal of non-wholly owned subsidiary						268	268
Acquisition of non-wholly owned subsidiary	(755)				(755)	680	(75)
Balance at end of the period at Jun. 30, 2020	41,535	2,383	99,492	70	(60,410)	(53)	41,482
Balance at beginning of the period at Dec. 31, 2020	65,682	2,654	125,916	(48)	(62,840)	95	65,777
Loss for the period	(12,955)				(12,955)	46	(12,909)
Other comprehensive loss	(70)			(70)			(70)
Total comprehensive loss	(13,025)	0	0	(70)	(12,955)	46	(12,979)
Share-based payments	4,276		4,276				4,276
Exercise of options		39	(39)
Balance at end of the period at Jun. 30, 2021	€ 56,933	€ 2,693	€ 130,153	€ (118)	€ (75,795)	€ 141	€ 57,074

- Definition

The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners.

+ References + Details

- Definition

The amount of residual interest in the assets of the entity after deducting all its liabilities.

+ References + Details

- Definition

The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 7
-IssueDate 2020-01-01
-Paragraph 18
-Subparagraph b
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2020-en-r&anchor=para_18_b&doctype=Standard
-URIDate 2020-01-01

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 1
-IssueDate 2020-01-01
-Paragraph 24
-Subparagraph b
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2020-en-r&anchor=para_24_b&doctype=Standard
-URIDate 2020-01-01

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 1
-IssueDate 2020-01-01
-Paragraph 32
-Subparagraph a
-Clause ii
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2020-en-r&anchor=para_32_a_ii&doctype=Standard
-URIDate 2020-01-01

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 8
-IssueDate 2020-01-01
-Paragraph 28
-Subparagraph b
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2020-en-r&anchor=para_28_b&doctype=Standard
-URIDate 2020-01-01

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Note Effective on first application of IFRS 9
-Name IFRS
-Number 4
-IssueDate 2020-01-01
-Paragraph 39L
-Subparagraph e
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=4&code=ifrs-tx-2020-en-b&anchor=para_39L_e&doctype=Standard
-URIDate 2020-01-01

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 8
-IssueDate 2020-01-01
-Paragraph 23
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2020-en-r&anchor=para_23&doctype=Standard
-URIDate 2020-01-01

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Name IFRS
-Number 12
-IssueDate 2020-01-01
-Paragraph B10
-Subparagraph b
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2020-en-r&anchor=para_B10_b&doctype=Appendix&subtype=B
-URIDate 2020-01-01

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 1
-IssueDate 2020-01-01
-Paragraph 106
-Subparagraph d
-Clause i
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_106_d_i&doctype=Standard
-URIDate 2020-01-01

Reference 9: http://www.xbrl.org/2003/role/exampleRef
-Note Effective 2021-01-01
-Name IFRS
-Number 17
-IssueDate 2020-01-01
-Paragraph 113
-Subparagraph b
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2020-en-r&anchor=para_113_b&doctype=Standard
-URIDate 2020-01-01

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 1
-IssueDate 2020-01-01
-Paragraph 81A
-Subparagraph a
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_81A_a&doctype=Standard
-URIDate 2020-01-01

+ Details

General company information

6 Months Ended

Jun. 30, 2021

General company information

General company information

1General company information

Centogene N.V. (“the Company”) and its subsidiaries (“the Group”) focus on rare diseases and seek to transform real-world clinical and genetic or other data into actionable information for patients, physicians and pharmaceutical companies. The mission of the Company is to bring rationality to treatment decisions and to accelerate the development of new orphan drugs by using our knowledge of the global rare disease market, including epidemiological and clinical data and innovative biomarkers.

On November 7, 2019, the Company completed an initial public offering (“IPO”) and has since been listed on Nasdaq Global Market under stock code “CNTG”. Centogene N.V. is a public company with limited liability incorporated in the Netherlands, with registered office located at Am Strande 7 in 18055 Rostock, Germany and Dutch trade register number 72822872.

In July 2020, the Company completed a follow-on offering of 3,500,000 common shares of the Company (the “Follow-on Equity Offering”), consisting of 2,000,000 common shares offered by the Company and 1,500,000 common shares offered by selling shareholders at a price to the public of USD 14.00 per common share (i.e. EUR 12.71 per share). Aggregate offering proceeds, net of underwriting discounts, commissions and transaction costs, were EUR 22 million to the Company.

Basis of preparation

6 Months Ended

Jun. 30, 2021

Basis of preparation

Basis of preparation

2Basis of preparation

The interim condensed consolidated financial statements for the three and six months ended June 30, 2020 and 2021 have been prepared in accordance with IAS 34 Interim Financial Reporting.

The interim condensed consolidated financial statements do not include all the information and disclosures required in the annual financial statements, and should be read in conjunction with the Group’s annual consolidated financial statements as of December 31, 2019 and 2020 and for the three years ended December 31, 2020. Unless otherwise specified, "the Company" refers to Centogene N.V. and Centogene GmbH throughout the remainder of these notes, while "the Group" refers to Centogene N.V., Centogene GmbH and its subsidiaries.

The accounting policies adopted in the preparation of the interim condensed consolidated financial statements are consistent with those followed in the preparation of the Group’s annual consolidated financial statements for the year ended December 31, 2020. The Group has not early adopted any standard, interpretation or amendment that has been issued but is not yet effective, and there are no new or amended standards or interpretations that are issued and became effective for the 2021 annual reporting period, that have a material impact on the Group.

These interim condensed consolidated financial statements are presented in euro, which is the Group's functional currency. Unless otherwise specified, all financial information presented in euro is rounded to the nearest thousand (EUR k) in line with customary commercial practice.

Effect of COVID-19 Pandemic

6 Months Ended

Jun. 30, 2021

Effect of COVID-19 Pandemic

Effect of COVID-19 Pandemic

3Effect of COVID-19 Pandemic

The COVID-19 pandemic has spread worldwide and continues to cause many governments to maintain measures to slow the spread of the outbreak through quarantines, travel restrictions, closures of borders and requiring maintenance of physical distance between individuals.

Since the second quarter of 2020, the COVID-19 pandemic has resulted in a slowdown in our Diagnostics and Pharmaceutical businesses. As part of the Company’s initiative to assist local, national and international authorities as well as other partners in their efforts to facilitate the earliest possible diagnosis of COVID-19 and thereby contribute to allowing society to return to a “new” normal, the Company commenced testing for COVID-19 in March 2020.

During the six months ended June 30, 2021, the Group continued the COVID-19 testing activities started in 2020 with a leading role in providing testing services at airports in Germany. Furthermore, new variants of the virus have emerged since mid-December 2020. How these mutations develop and their impact on the effectiveness of vaccines is not yet fully clear. Furthermore, vaccination campaigns in several countries started during the six months ended June 30, 2021, and due to the expected increase in the availability of vaccines until the end of the year, the expectation is that governments will reduce restrictions during 2021. How and when this would affect the potential prolongation of the need for testing on a broader scale is not clear yet.

Although the Group is taking a number of measures aimed at minimizing disruptions to the business and operations, and while the provision of testing for the COVID-19 virus is anticipated to generate additional revenues for us, the full extent to which the global COVID-19 pandemic may impact the business will depend on future developments, which are highly uncertain and cannot be predicted, such as the duration of the pandemic, the availability of vaccines, the probability of the occurrence of further outbreaks and the ultimate impact on the financial markets and the global economy, and could result in an unforeseen negative impact on the business and future results of operations.

Revenues from contracts with customers

6 Months Ended

Jun. 30, 2021

Revenues from contracts with customers

Revenues from contracts with customers

4Revenues from contracts with customers


in EUR k	Three Months Ended June 30, 2020⁽¹⁾
	Pharmaceutical	Diagnostics	COVID-19	Total
Rendering of services	3,606	3,684	2,053	9,343
Sales of goods	334	—	42	376
Total Revenues from contracts with external customers	3,940	3,684	2,095	9,719

Recognized over time	3,606	3,684	522	7,812
Recognized at a point in time	334	—	1,573	1,907
Total Revenues from contracts with external customers	3,940	3,684	2,095	9,719

Geographical information
Europe	23	1,109	2,095	3,227
—Germany#*	19	1	2,095	2,115
—Netherlands**	—	—	—	—
Middle East	45	1,789	—	1,834
—Saudi Arabia#	—	1,106	—	1,106
North America	3,872	501	—	4,373
—United States#	3,872	493	—	4,365
Latin America	—	219	—	219
Asia Pacific	—	66	—	66
Total Revenues from contracts with external customers	3,940	3,684	2,095	9,719

(1)	Since the COVID-19 business has been reported as a separate segment as from the third quarter of 2020, the comparative figures for the three and six months ended June 30, 2020 were adjusted retrospectively for both the COVID-19 and diagnostics segments.


in EUR k	Three Months Ended June 30, 2021
	Pharmaceutical	Diagnostics	COVID-19	Total
Rendering of services	2,653	6,715	42,325	51,693
Sales of goods	178	—	—	178
Total Revenues from contracts with external customers	2,831	6,715	42,325	51,871

Recognized over time	2,653	6,715	7,128	16,496
Recognized at a point in time	178	—	35,197	35,375
Total Revenues from contracts with external customers	2,831	6,715	42,325	51,871

Geographical information
Europe	49	1,320	42,161	43,530
—Germany#*	—	57	40,323	40,380
—Netherlands**	—	3	1,771	1,774
Middle East	26	3,950	—	3,976
North America	2,731	690	164	3,585
Latin America	25	608	—	633
Asia Pacific	—	147	—	147
Total Revenues from contracts with external customers	2,831	6,715	42,325	51,871

*country of the incorporation of Centogene GmbH

**country of the incorporation of Centogene N.V.

#	countries contributing more than 10% of the Group’s total consolidated revenues for the three months ended June 30, 2020 and 2021, respectively.


in EUR k	Six months ended June 30, 2020⁽¹⁾
	Pharmaceutical	Diagnostics	COVID-19	Total
Rendering of services	7,880	11,226	2,066	21,172
Sales of goods	610	—	42	652
Total Revenues from contracts with external customers	8,490	11,226	2,108	21,824

Recognized over time	7,880	11,226	535	19,641
Recognized at a point in time	610	—	1,573	2,183
Total Revenues from contracts with external customers	8,490	11,226	2,108	21,824

Geographical information
Europe	67	2,713	2,108	4,888
—Germany#*	38	61	2,108	2,207
—Netherlands**	—	3	—	3
Middle East	48	6,204	—	6,252
—Saudi Arabia#	—	4,139	—	4,139
North America	8,375	1,121	—	9,496
—United States#	8,375	964	—	9,339
Latin America	—	965	—	965
Asia Pacific	—	223	—	223
Total Revenues from contracts with external customers	8,490	11,226	2,108	21,824

(1)	Since the COVID-19 business has been reported as a separate segment as from the third quarter of 2020, the comparative figures for the six months ended June 30, 2020 were adjusted retrospectively for both the COVID-19 and diagnostics segments.


in EUR k	Six months ended June 30, 2021
	Pharmaceutical	Diagnostics	COVID-19	Total
Rendering of services	6,046	13,098	97,302	116,446
Sales of goods	383	—	2	385
Total Revenues from contracts with external customers	6,429	13,098	97,304	116,831

Recognized over time	6,046	13,098	18,972	38,116
Recognized at a point in time	383	—	78,332	78,715
Total Revenues from contracts with external customers	6,429	13,098	97,304	116,831

Geographical information
Europe	198	2,534	96,282	99,014
—Germany#*	—	110	92,668	92,778
—Netherlands**	—	5	3,539	3,544
Middle East	55	8,085	—	8,140
North America	6,136	1,154	944	8,234
—United States	6,136	1,045	944	8,125
Latin America	40	1,018	—	1,058
Asia Pacific	—	307	78	385
Total Revenues from contracts with external customers	6,429	13,098	97,304	116,831

*country of the incorporation of Centogene GmbH

**country of the incorporation of Centogene N.V.

#	countries contributing more than 10% of the Group’s total consolidated revenues for the six months ended June 30, 2020 and 2021, respectively.

The Group collaborated with a range of pharmaceutical partners on a worldwide basis in 2020 and 2021. In addition, in cases where pharmaceutical partners are developing a new rare disease treatment, it is generally anticipated that

the final approved treatment will be made available in several countries or globally. As a result, the Group allocates the revenues of the pharmaceutical segment by geographical region by reference to the location where each pharmaceutical partner mainly operates, which is based on the region from which most of their revenues are generated. The allocation of revenues in the diagnostics segment and COVID-19 segments is based on the location of each customer.

Pharmaceutical segment

During the three and six months ended June 30, 2021, revenues from one pharmaceutical partner represented 4.1% and 4.4%, respectively, of the Group's total revenues (the three and six months ended June 30, 2020: 26.2% and 26.4%, respectively).

COVID-19 segment

During the three months ended June 30, 2021, revenues from two COVID-19 partners represented 5.2% and 12.9%, respectively, of the Group’s total revenues (the three months ended June 30, 2020: nil). In the six months ended June 30, 2021, revenues from two COVID-19 partners represented 4.7% and 15.2%, respectively, of the Group’s total revenues (the six months ended June 30, 2020: nil).

To support the COVID-19 test offerings, the Company acquired laboratory facilities and equipment, developed CENTOGENE’s Corona Test Portal and leased laboratory space at several locations in Germany. Additionally, COVID-19 testing capacity is provided through custom-built CentoTrucks, mobile laboratories in a container setup to carry out the COVID-19 analysis. Total investments in COVID-19 testing for the three and six months ended June 30, 2021 amounted to EUR 618k and EUR 2,034k, respectively, in property, plant and equipment (the three and six months ended June 30, 2020: EUR 1,873k and EUR 1,903k, respectively). An amount of EUR 354k is included in intangible assets and relates to the development of CENTOGENE’s Corona Test Portal for the six months ended June 30, 2021, no investments in intangibles were made in the three months ended June 30, 2021 (the three and six months ended June 30, 2020: EUR 527k and EUR 527k, respectively).

Segment information

6 Months Ended

Jun. 30, 2021

Segment information

Segment information

5Segment information


in EUR k	Three months ended June 30, 2020
	Pharmaceutical	Diagnostics	COVID-19	Corporate	Total
Total Revenues from contracts with external customers	3,940	3,684	2,095	—	9,719

Adjusted EBITDA	1,799	(1,636)	812	(8,395)	(7,420)

Capital Expenditures
Additions to property, plant and equipment and right-of-use assets	301	200	1,873	1,249	3,623
Additions to intangible assets	1,852	—	527	395	2,774

Other segment information
Depreciation and amortization	389	563	54	1,342	2,348
Research and development expenses	—	—	—	3,119	3,119


in EUR k	Three Months Ended June 30, 2021
	Pharmaceutical	Diagnostics	COVID-19	Corporate	Total
Total Revenues from contracts with external customers	2,831	6,715	42,325	—	51,871

Adjusted EBITDA	647	580	6,251	(9,544)	(2,066)

Capital Expenditures
Additions to property, plant and equipment and right-of-use assets	3	—	618	105	726
Additions to intangible assets	241	—	—	522	763

Other segment information
Depreciation and amortization	410	412	1,069	1,493	3,384
Research and development expenses	—	—	—	4,053	4,053


	Six Months Ended June 30, 2020
in EUR k	Pharmaceutical	Diagnostics	COVID-19	Corporate	Total
Total Revenues from contracts with external customers	8,490	11,226	2,108	—	21,824

Adjusted EBITDA	4,407	(1,358)	621	(16,107)	(12,437)

Capital Expenditures
Additions to property, plant and equipment and right-of-use assets	301	987	1,903	1,836	5,027
Additions to intangible assets	2,854	—	527	584	3,965

Other segment information
Depreciation and amortization	1,071	1,107	54	2,200	4,432
Research and development expenses	—	—	—	5,810	5,810


	Six Months Ended June 30, 2021
in EUR k	Pharmaceutical	Diagnostics	COVID-19	Corporate	Total
Total Revenues from contracts with external customers	6,429	13,098	97,304	—	116,831

Adjusted EBITDA	2,144	1,633	16,418	(21,563)	(1,368)

Capital Expenditures
Additions to property, plant and equipment and right-of-use assets	9	234	2,034	419	2,696
Additions to intangible assets	563	—	354	1,172	2,089

Other segment information
Depreciation and amortization	824	818	1,996	3,032	6,670
Research and development expenses	—	—	—	8,388	8,388

Adjustments to EBITDA

Adjustments to EBITDA include non-cash charges in relation to depreciation, amortization (including impairments), and share-based payments as well as net financial costs, and income taxes. Certain costs, and related income, are not allocated to the reporting segment results and represent the residual operating activities of the Group reported as ‘Corporate’. These include corporate overheads, which are responsible for centralized functions such as communications, information technology, facilities, legal, finance and accounting, insurance (D&O), human resources, business development and strategic initiatives, certain professional and consulting services, procurement, research and development and other supporting activities.

Increases in corporate expenses for the three and six months ended June 30, 2021 are mainly due to increased personnel costs and administrative costs and additional investments in IT support and data center costs.

Reconciliation of segment Adjusted EBITDA to Group loss for the period


For the three months ended June 30	2020	2021
Reported segment Adjusted EBITDA	975	7,477
Corporate expenses	(8,395)	(9,543)
	(7,420)	(2,066)
Share-based payment expenses (Note 11)	(336)	(2,234)
Depreciation and amortization	(2,348)	(3,384)
Operating loss	(10,104)	(7,684)
Financial costs, net	(256)	(212)
Income tax expenses	—	(124)
Loss for the three months ended June 30	(10,360)	(8,020)


For the six months ended June 30	2020	2021
Reported segment Adjusted EBITDA	3,670	20,195
Corporate expenses	(16,107)	(21,563)
	(12,437)	(1,368)
Share-based payment expenses (Note 11)	(1,393)	(4,276)
Depreciation and amortization	(4,432)	(6,670)
Operating loss	(18,262)	(12,314)
Financial costs, net	(705)	(471)
Income tax expenses	(129)	(124)
Loss for the six months ended June 30	(19,096)	(12,909)

Non-current asset locations

Non-current assets of the Group consist of right-of-use assets (under IFRS 16), property, plant and equipment, as well as intangible assets. All of such assets are located in Germany, which is the country of the business address of Centogene GmbH, except for property, plant and equipment of EUR 460k (December 31, 2020: EUR 516k) and right-of-use assets of EUR 449k (December 31, 2020: EUR 709k), which are located in the United States.

Other income and expenses

6 Months Ended

Jun. 30, 2021

Other income and expenses

Other income and expenses

6Other income and expenses

6.1Other operating income


	For the Three months ended June 30		For the Six months ended June 30
in EUR k	2020	2021	2020	2021
Government grants	703	837	1,405	1,177
Others	98	439	341	465
Total other operating income	801	1,276	1,746	1,642

Government grants include performance-based grants to subsidize research, development and innovation in the state of Mecklenburg-Western Pomerania from funds granted by the European Regional Development Fund. Furthermore, government grants contain the release of deferred income from investment related grants. Other operating income includes the bank loan granted under the Coronavirus Aid, Relief, and Economic Security Act (CARES Act) which was forgiven during the three months ended June 30, 2021 (see note 10).

6.2Other operating expenses


	For the Three months ended June 30		For the Six months ended June 30
in EUR k	2020	2021	2020	2021
Currency losses	37	(8)	37	26
Others	—	10	101	10
Total other operating expenses	37	2	138	36

During the six months ended June 30, 2020, the Group disposed of its entire 51% interest in LPC GmbH (“LPC”) to the minority shareholders for a consideration of EUR 213k, of which EUR 200k is to be paid over a period of four years (and included in other assets, see note 7). The related non-controlling interest of EUR 268k (accumulated share of loss) was debited to profit or loss, and the sale resulted in a loss of EUR 101k.

Trade receivables and other assets

6 Months Ended

Jun. 30, 2021

Trade receivables and other assets

Trade receivables and other assets

7Trade receivables and other assets


in EUR k	Dec 31, 2020	June 30, 2021
Non‑current
Other assets - Rental deposits	1,867	2,923
Other assets – Others	100	100
	1,967	3,023
Current
Trade receivables, net	25,656	15,630
Contract assets, net	3,543	2,860
Other assets	8,286	6,064
	37,485	24,554
Total non-current and current trade receivables and other assets	39,452	27,577

Other non-current assets

The non-current portion of other assets mainly include cash deposits of EUR 2,250k used to secure a bank guarantee of EUR 3,000k relating to the leases of the Rostock headquarters building, cash deposits of EUR 192k, used to secure a bank guarantee of EUR 257k, relating to the leases of the Berlin office and EUR 285k for the leases of certain plant and machineries. It also includes the non-current part of the consideration receivable for the sale of LPC for EUR 100k. (see note 6.2).

Trade receivables and contract assets

Trade receivables are non-interest bearing and are generally due in 30 to 90 days. In general, portfolio-based expected credit loss allowances are recognized on trade receivables and contract assets.


in EUR k	Dec, 2020		June 30, 2021
Not past due	24,185		11,826
Past due 1-30 days	2,228		3,293
Past due 31-90 days	797		2,474
Past due more than 90 days	6,757		6,275
Total gross amount of trade receivables and contract assets	33,967		23,868

Expected credit loss rate
Not past due	1.6	%	1.2	%
Past due 1-30 days	3.1	%	3.6	%
Past due 31-90 days	7.7	%	11.8	%
Past due more than 90 days	63.0	%	77.0	%
Expected credit loss rate on total gross trade receivables and contract assets	14.0	%	22.7	%

Expected credit loss	4,768		5,378

The addition to the allowance for expected credit losses amounts to EUR 580k and EUR 675k for the three and six months ended June 30, 2021, respectively, which was included in the impairment of financial assets in the profit and loss account (the three and six months ended June 30, 2020: EUR 500k and EUR 1,674k).

Other current assets

The current assets include no VAT receivables (December 31, 2020: EUR 226k), prepaid expenses of EUR 2,873k (December 31, 2020: EUR 4,431k), receivables related to exercised share-based payment grants of EUR 283k (December 31, 2020: EUR 1,253k receivables), receivables related to COVID-19 bank or credit card transactions of EUR 435k (December 31, 2020: EUR 1,076k), as well as receivables from grants of EUR 1,280k (December 31, 2020: EUR 442k).

Cash and short-term deposits

6 Months Ended

Jun. 30, 2021

Cash and short-term deposits

Cash and short-term deposits

8Cash and short-term deposits

As of June 30, 2021, the Group has pledged its short-term deposits with carrying amount of EUR 1,500k (December 31, 2020: EUR 1,500k) and EUR 2,500k (December 31, 2020: EUR 2,500k) respectively, to fulfil collateral requirements in respect of existing secured bank loan and overdraft facility up to EUR 2,500k. In addition, the Group has pledged its short-term deposits of EUR 1,000k (December 31, 2020: EUR 1,000k) related to two other overdraft facilities worth EUR 500k each.

The restriction applying to the collateral may be terminated at any time subject to the full amount of the relevant bank loans and the overdrafts being repaid.

Equity

6 Months Ended

Jun. 30, 2021

Equity.

Equity

9Equity

Common Shares

As of June 30, 2021, 22,445,242 common shares of Centogene N.V. with a nominal value of EUR 0.12 were issued and fully paid up (December 31, 2020: 22,117,643). As of June 30, 2021, the authorized but unissued common share capital amounted to EUR 6,787k (December 31, 2020: EUR 6,826k).

The holders of common shares are entitled to the Company's approved dividends and other distributions as may be declared from time to time by the Company, and are entitled to vote per share on all matters to be voted at the Company's annual general meetings.

Capital reserve

As of June 30, 2021, capital reserve included a share premium of EUR 107,459k (December 31, 2020: EUR 107,498k), being amounts paid in by shareholders at the issuance of shares in excess of the par value of the shares issued, net of any transaction costs incurred for the share issuance.

In addition, it also included amounts recorded on the basis of share-based payments. For additional information on the share-based payments, see note 11.

Financial liabilities

6 Months Ended

Jun. 30, 2021

Financial liabilities

Financial liabilities

10Financial liabilities

10.1Interest-bearing liabilities


in EUR k	Dec 31, 2020	June 30, 2021
Non‑current liabilities
Non‑current portion of secured bank loans	401	200
Total non‑current loans	401	200
Lease liabilities	17,677	16,209
Total non‑current liabilities	18,078	16,409

Current liabilities
Current portion of secured bank loans	567	567
Other bank loans	387	—
Bank overdrafts	1,538	3,316
Total current loans	2,492	3,883
Current portion of lease liabilities	3,528	3,299
Total current liabilities	6,020	7,182

Total non‑current and current liabilities	24,098	23,591

As of June 30, 2021, short-term cash deposits of EUR 1,500k (December 31, 2020: EUR 1,500k were used to secure the secured bank loan outstanding (see note 8).

Other bank loans outstanding as of December 31, 2020 represented bank loans granted under the Coronavirus Aid, Relief, and Economic Security Act (CARES Act) which were forgiven during the three months ended June 30, 2021. The amount forgiven has been included in other operating income (see note 6).

The following table is based on the original terms and conditions:

Conditions and statement of liabilities

The outstanding interest-bearing liabilities as of June 30, 2021 and December 31, 2020 have the following conditions:


				Dec 31, 2020		June 30, 2021
				Nominal	Carrying	Nominal	Carrying
in EUR k	Currency	Nominal interest rate	Maturity	amount	amount	amount	amount
Secured bank loan	EUR	2.95%	2017‑22	968	968	767	767
Other bank loan	USD	1%	2020-22	387	387	—	—
Bank overdrafts	EUR	4.75%	Rollover	498	498	496	496
Bank overdrafts	EUR	3.75%	Rollover	628	628	2,324	2,324
Bank overdrafts	EUR	4.50%	Rollover	412	412	496	496
Lease liabilities	EUR	2.1%-3.5%*, 5.4%-9.1%	2017-31	21,205	21,205	19,508	19,508
Total interest‑bearing financial liabilities				24,098	24,098	23,591	23,591

*	represents the incremental borrowing rate of the Group at the commencement of the leases

The bank overdrafts of EUR 2,324k as of June 30, 2021 (December 31, 2020: EUR 628k) were secured by short-term deposits with a carrying amount of EUR 2,500k (December 31, 2020: EUR 2,500k) (see note 8). The other bank overdrafts of EUR 992k (December 31, 2020: EUR 910k) were secured over two short-term deposits with a carrying amount of EUR 500k each (see note 8).

10.2Trade payables and other liabilities


in EUR k	Dec 31, 2020	June 30, 2021
Trade payables	31,736	14,014
Government grants (deferred income)	10,292	9,992
Contract liabilities	4,479	4,913
Others	13,483	10,813
Trade payables and other liabilities	59,990	39,732
Non‑current	8,950	8,640
Current	51,040	31,092

Government grants mainly include investment-related government grants. These were received for the purchase of certain items of property, plant and equipment for the research and development facilities in Mecklenburg-Western Pomerania, including the Rostock facility. The grants were issued in the form of investment subsidies as part of the joint federal and state program, "Verbesserung der regionalen Wirtschaftsstruktur" (improvement of the regional economic structure) in connection with funds from the European Regional Development Fund. No additional grants were received during the six months ended June 30, 2021 related to the purchase of certain items of property, plant and equipment (the six months ended June 30, 2020: EUR 390k).

In addition, other liabilities include a provision for outstanding invoices of EUR 4,931k (December 31, 2020: EUR 1,245k), personnel-related liabilities for vacation and bonuses totaling EUR 3,245k (December 31, 2020: EUR 4,032k), VAT payable of EUR 119k (December 31, 2020: EUR 4,578k payable), as well as liabilities for wage and church tax of EUR 920k (December 31, 2020: EUR 1,988k).

Share-based payments

6 Months Ended

Jun. 30, 2021

Share-based payments.

Share-based payments

11Share-based payments

Expenses from share-based payment arrangements

During the three and six months ended June 30, 2021, the Company incurred share-based payment expenses of EUR 2,234k and EUR 4,276k, respectively (the three and six months ended June 30, 2020: EUR 336k and EUR 1,393k, respectively). These expenses were included in general administrative expenses for services received during the respective periods.

Share-based award activity

A detailed description of the Company’s share-based payment arrangements is included in Note 20 of the Group’s annual consolidated financial statements for the year ended December 31, 2020. During the six months ended June 30, 2021 there were no changes to the terms and conditions of the Company’s share-based payment arrangements.

The following table presents a summary of the Company’s share-based payment arrangement activity for the six months ended June 30, 2021.


	ESOP 2017		2019-2021 awards ⁽¹⁾
number of awards (options and RSUs)	Number	WAEP	Number of options	WAEP (USD)	Number of RSUs	WAEP
Outstanding as of January 1	549,005	0.12	154,925	11.60	1,885,100	—
Granted during the year(1)	—	0.12	30,152	12.57	150,804	—
Exercised during the year	(140,169)	0.12	—	—	(187,430)	—
Outstanding as of June 30	408,836	0.12	185,077	11.76	1,848,474	—
Vested as of June 30	408,836		111,591		230,992
Exercisable as of June 30	408,836		111,591		230,992

(1)

The granted and outstanding options and RSUs do not include the number of awards for which the service period has commenced in advance of grant date. The number of these options and RSUs to be granted is not fixed until the relevant grant date as the number is dependent on the achieved value of the award divided by the trailing volume-weighted average stock price of the Company, pursuant to the terms of the underlying award agreements. These include RSUs to be granted to the new CEO from 2022, the annual RSU award to be granted in 2022 to an executive officer, and the RSUs and options to be granted to certain supervisory board members annually in 2022 and thereafter.

The option and RSUs for the years 2019-2021 as included in the table above reflect the activity related to the share-based payment awards ESOP 2019, management, supervisory board and employees.

Grants awarded

During the six months ended June 30, 2021 the following awards were granted:


Award Type (2019 Plan)	Market/ Performance Based Vesting Conditions	Number of Awards	Vesting Conditions	Expiration Date
RSUs	No	105,804	Four equal tranches over a four-year period, starting January 1, 2022, April 1, 2022 or on each anniversary of the grant date	10th anniversary of Grant Date
RSUs	No	30,000	Three equal tranches over a three-year period starting January 1, 2022	10th anniversary of Grant Date
RSUs	No	15,000	Three equal tranches of which the first tranche vested immediately and the two remaining annual tranches will vest starting January 1, 2022	10th anniversary of Grant Date
Options	No	15,152	Four equal tranches over a four-year period following each anniversary of the grant date	10th anniversary of Grant Date
Options	Yes	15,000	Three equal tranches over a three-year period starting January 1, 2022	10th anniversary of Grant Date

The grant date fair value of these grants will be recognized in profit or loss over the service period by using the graded approach.

15,000 of the options referred to above vest only if the 20 trading day volume-weighted average stock price of the Company’s shares preceding the vesting date of each tranche exceeds the exercise price of USD 12.52. This hurdle is considered a market condition. Therefore, expenses would not be reversed, if the tranches do not ultimately vest. The other options have no market or performance-based vesting conditions.

The RSUs referred to above have no market or performance-based vesting conditions. Each RSU represents a right to receive a payment in cash or shares equal to the value of the RSU at the exercise date. The Company has a choice to settle either in cash, in shares or a combination thereof. In line with this, both types of awards are to be settled in shares and expire on the 10th anniversary of the grant date.

Additionally, during the three months ended June 30, 2021 the Company entered into an award agreement with an executive officer under which the officer shall receive annual RSU awards to be granted following each fiscal year, upon approval by the Supervisory Board, based upon achievement of the officer’s annual variable remuneration target. The service period of the annual RSUs to be granted in 2022 has commenced during the three months ended June 30, 2021, corresponding with the employment start date, as entitlement to the RSU grant is dependent on continuing service with the Company through the grant date and annual variable remuneration target. However, the grant date criteria for these awards will not be met until such time the value of the award and number of RSUs to be granted are approved and fixed pursuant to the underlying award agreement.

During the six months ended June 30, 2021, an award of 75,000 options granted in 2020 has been modified by removing the condition that the 20 trading day volume-weighted average stock price of the Company’s share preceding the vesting date of each tranche exceeds the exercise price of USD 11.60. This change was accounted for as a modification under IFRS 2 and the incremental fair value of USD 226k will be recorded in the statement of comprehensive income over the vesting period of the remaining grant, together with the remaining original grant date fair value yet to be recognised.

The fair value of the RSUs is based on the observed value of the underlying shares. As no dividend payments are expected over the vesting period, no further adjustment is required. The weighted average fair value of RSUs granted under the 2019 Plan during the three months and six months ended June 30, 2021 was USD 10.17 and USD 10.91, respectively. The fair value of the options awarded is determined using a Monte Carlo simulation model. The Monte Carlo simulation model utilizes multiple input variables to estimate the probability that market conditions will be achieved. The weighted average fair value of the options granted under the 2019 Plan during the three months ended June 30, 2021 was USD 7.59 and USD 7.47, respectively.

Exercises

During the six months ended June, 2021, 140,169 ESOP 2017 options were exercised. The weighted average share price at the date of exercise was USD 11.67. During the six months ended June 30, 2021, 187,430 RSUs were exercised. The weighted average share price at the date of exercise was USD 11.74.

Commitments

6 Months Ended

Jun. 30, 2021

Commitments

Commitments

12Commitments

Future payments for non-cancellable leases

The Group has various lease contracts in relation to the expansion of the Rostock headquarters and leasing of the Frankfurt laboratory, Airport Berlin, Airport Düsseldorf, Airport Cologne/ Bonn, Airport Munich, Airport Frankfurt and additional laboratory space in Hamburg. The future lease payments and utilities for these non-cancellable lease contracts are EUR 1,667k within one year, EUR 2,424k within five years and EUR 4,219k thereafter (December 31, 2020: EUR 283k, EUR 1,686k and EUR 4,855k respectively).

The Group has various non-cancellable lease contracts of office equipment and storage spaces which had a lease term of less than 12 months or were related to leases of low-value assets, and therefore the short-term lease recognition exemption was applied to these contracts. The future lease payments for these non-cancellable lease contracts are EUR 16k within one year (December 31, 2020: EUR 33k) and EUR 2k within five years (December 31, 2020: EUR 9k).

Future payment obligations

As of June 30, 2021, the Group concluded agreements with suppliers, for goods and services to be provided subsequent to June 30, 2021 with a total payment obligation of approximately EUR 2,857k (December 31, 2020: EUR 4,669k).

Contingent Liabilities

6 Months Ended

Jun. 30, 2021

Contingent Liabilities

Contingent Liabilities

13Contingent Liabilities

●

In May 2016, the Company was informed in writing by the Universitair Medisch Centrum Utrecht ("UMCU") that a claim had been initiated against UMCU regarding a prenatal diagnostic test that the Company conducted at their request which failed to identify a specific mutation present in a patient. On October 1, 2018, the UMCU and Neon Underwriting Limited formally filed a legal claim in the local court in Rostock, Germany against the Company alleging that the Company’s negligence in performing the test resulted in the misdiagnosis of the patient. UMCU is seeking recovery for compensatory damages as a result of the alleged misdiagnosis. By court order of November 8, 2018, the Regional Court of Rostock set the amount in dispute at EUR 880k.

On November 12, 2018, the Company submitted a notice to the Regional Court of Rostock with the intention to defend against the claim. On January 3, 2019, the Company filed a motion to dismiss in which the Company denied the merits of the claim. UMCU and Neon Underwriting Limited responded to this motion on March 15, 2019 with a statement of reply, and the parties have since made several court filings setting out their arguments since. By order dated June 3, 2019, the Regional Court of Rostock provided a first set of questions to be answered by an expert witness. Following a request by the Court, the Director of the Institute of Genetics at the University of Bonn recommended a professor for human genetics from the University of Aachen be appointed as an expert witness in this case. The Company agreed to such recommendation.

As of June 30, 2021, the amount in dispute was EUR 1.3 million. The matter was assigned to a new judge, due to the illness of the prior judge, and the decision to appoint the recommended expert witness is still pending.

The Company intends to continue to rigorously defend its position and considers that it is not probable the legal claim towards the Company will be successful and as a result has not recognized a provision for this claim as of June 30, 2021. In addition, in case a settlement would be required, the Company believes that the corresponding liability will be fully covered by the respective existing insurance policies.

●

Certain of our original shareholders agreed to reimburse us for the payments that we make to option holders under the 2016 Plan. Upon completion of the Follow-on Equity Offering, the relevant payables to the holders of vested options were settled mainly by the proceeds received from such original shareholders from the sale of their shares in the Follow-on Equity Offering. We have received a demand from one such original shareholder that alleges that it should have paid less to us in connection with the settlement of such payables. We believe such demand to be baseless and, should such original shareholder institute formal legal proceedings against us, intend to defend our interests vigorously.

●

The higher regional court of Rostock issued a final decision by which it has retroactively invalidated a contract entered into between Centogene GmbH (the “Company”) and the State of Mecklenburg-Western Pomerania (“MVP”) for COVID-19 testing, due to non-compliance by MVP with the public tender requirements of the German government. As a result of the invalidation, MVP now has a claim under German law against the Company for repayment of the full amount invoiced and received under the contract (EUR 2.3 million). The Company also has a claim against MVP for compensation for the value of services provided in expectation of the validity of the contract.

The understanding between MVP and Centogene is that the Company’s services were provided at market value and that despite the court’s invalidation of the contract, Centogene has a claim against MVP for EUR 2.3 million. Thus the amounts of these two claims would be expected to equal each other and could be

offset against one another. A contractual agreement putting this understanding in writing has been finalized and signed.

Subsequent Events

6 Months Ended

Jun. 30, 2021

Subsequent Events

Subsequent Events

14Subsequent Events

Grant of restricted stock units

In the third quarter of 2021, 22,936 RSUs were granted to management, subject to the terms of the 2019 Plan and the applicable award agreement. The RSUs will vest in four equal tranches over a four-year period starting August 16, 2021.

Grants to CEO

In 2020 the Company and the new CEO entered into an award agreement under the 2019 Plan pursuant to which the CEO will receive certain awards in the form of RSUs, which have no exercise price. According to the agreement, a total of 324,000 RSUs were granted to the CEO on December 1, 2020, subject to the purchase of ordinary shares of the Company in the amount of CHF 1,000,000 within a certain period after the grant date. The CEO has initiated purchases under this program. Due to the short trading windows as defined in the Company’s insider trading rules in which the CEO was able to purchase shares, the Supervisory Board extended the period in which these purchases can be made and has agreed to allocate the grant pro rata to the percentage of the CHF 1,000,000 invested by the CEO in purchases of shares in the Company.

Legal settlement

In July 2021, Centogene GmbH and the State of Mecklenburg-Western Pomerania (“MVP”) entered into an agreement regarding Centogene’s cost compensation claim with respect to a previously invalidated COVID-19 testing contract. This settlement did not result in a required adjustment to the interim condensed consolidated financial statements.

Contingent Liability

On August 7, 2021, our partnering laboratory physician Prof. Dr. Peter Bauer was informed in writing by the Public Prosecutor's Office in Fulda that a criminal investigation had been initiated against him regarding allegedly falsely billing statements submitted to the Association of Statutory Health Insurance Physicians in Hessen (Kassenärztliche Vereinigung Hessen). The aggregate amount in question is EUR 42,268.50. The Company intends to support Prof. Dr. Peter Bauer in the defense of the case.

Revenues from contracts with customers (Tables)

6 Months Ended

Jun. 30, 2020

Revenues from contracts with customers

Schedule of geographical information


in EUR k	Three Months Ended June 30, 2020⁽¹⁾
	Pharmaceutical	Diagnostics	COVID-19	Total
Rendering of services	3,606	3,684	2,053	9,343
Sales of goods	334	—	42	376
Total Revenues from contracts with external customers	3,940	3,684	2,095	9,719

Recognized over time	3,606	3,684	522	7,812
Recognized at a point in time	334	—	1,573	1,907
Total Revenues from contracts with external customers	3,940	3,684	2,095	9,719

Geographical information
Europe	23	1,109	2,095	3,227
—Germany#*	19	1	2,095	2,115
—Netherlands**	—	—	—	—
Middle East	45	1,789	—	1,834
—Saudi Arabia#	—	1,106	—	1,106
North America	3,872	501	—	4,373
—United States#	3,872	493	—	4,365
Latin America	—	219	—	219
Asia Pacific	—	66	—	66
Total Revenues from contracts with external customers	3,940	3,684	2,095	9,719

(1)	Since the COVID-19 business has been reported as a separate segment as from the third quarter of 2020, the comparative figures for the three and six months ended June 30, 2020 were adjusted retrospectively for both the COVID-19 and diagnostics segments.


in EUR k	Three Months Ended June 30, 2021
	Pharmaceutical	Diagnostics	COVID-19	Total
Rendering of services	2,653	6,715	42,325	51,693
Sales of goods	178	—	—	178
Total Revenues from contracts with external customers	2,831	6,715	42,325	51,871

Recognized over time	2,653	6,715	7,128	16,496
Recognized at a point in time	178	—	35,197	35,375
Total Revenues from contracts with external customers	2,831	6,715	42,325	51,871

Geographical information
Europe	49	1,320	42,161	43,530
—Germany#*	—	57	40,323	40,380
—Netherlands**	—	3	1,771	1,774
Middle East	26	3,950	—	3,976
North America	2,731	690	164	3,585
Latin America	25	608	—	633
Asia Pacific	—	147	—	147
Total Revenues from contracts with external customers	2,831	6,715	42,325	51,871

*country of the incorporation of Centogene GmbH

**country of the incorporation of Centogene N.V.

#	countries contributing more than 10% of the Group’s total consolidated revenues for the three months ended June 30, 2020 and 2021, respectively.


in EUR k	Six months ended June 30, 2020⁽¹⁾
	Pharmaceutical	Diagnostics	COVID-19	Total
Rendering of services	7,880	11,226	2,066	21,172
Sales of goods	610	—	42	652
Total Revenues from contracts with external customers	8,490	11,226	2,108	21,824

Recognized over time	7,880	11,226	535	19,641
Recognized at a point in time	610	—	1,573	2,183
Total Revenues from contracts with external customers	8,490	11,226	2,108	21,824

Geographical information
Europe	67	2,713	2,108	4,888
—Germany#*	38	61	2,108	2,207
—Netherlands**	—	3	—	3
Middle East	48	6,204	—	6,252
—Saudi Arabia#	—	4,139	—	4,139
North America	8,375	1,121	—	9,496
—United States#	8,375	964	—	9,339
Latin America	—	965	—	965
Asia Pacific	—	223	—	223
Total Revenues from contracts with external customers	8,490	11,226	2,108	21,824

(1)	Since the COVID-19 business has been reported as a separate segment as from the third quarter of 2020, the comparative figures for the six months ended June 30, 2020 were adjusted retrospectively for both the COVID-19 and diagnostics segments.


in EUR k	Six months ended June 30, 2021
	Pharmaceutical	Diagnostics	COVID-19	Total
Rendering of services	6,046	13,098	97,302	116,446
Sales of goods	383	—	2	385
Total Revenues from contracts with external customers	6,429	13,098	97,304	116,831

Recognized over time	6,046	13,098	18,972	38,116
Recognized at a point in time	383	—	78,332	78,715
Total Revenues from contracts with external customers	6,429	13,098	97,304	116,831

Geographical information
Europe	198	2,534	96,282	99,014
—Germany#*	—	110	92,668	92,778
—Netherlands**	—	5	3,539	3,544
Middle East	55	8,085	—	8,140
North America	6,136	1,154	944	8,234
—United States	6,136	1,045	944	8,125
Latin America	40	1,018	—	1,058
Asia Pacific	—	307	78	385
Total Revenues from contracts with external customers	6,429	13,098	97,304	116,831

*country of the incorporation of Centogene GmbH

**country of the incorporation of Centogene N.V.

#	countries contributing more than 10% of the Group’s total consolidated revenues for the six months ended June 30, 2020 and 2021, respectively.

Segment information (Tables)

6 Months Ended

Jun. 30, 2021

Segment information

Schedule of segment information and reconciliation of segment adjusted EBITDA to group loss for the period

in EUR k

Reconciliation of segment Adjusted EBITDA to Group loss for the period


For the three months ended June 30	2020	2021
Reported segment Adjusted EBITDA	975	7,477
Corporate expenses	(8,395)	(9,543)
	(7,420)	(2,066)
Share-based payment expenses (Note 11)	(336)	(2,234)
Depreciation and amortization	(2,348)	(3,384)
Operating loss	(10,104)	(7,684)
Financial costs, net	(256)	(212)
Income tax expenses	—	(124)
Loss for the three months ended June 30	(10,360)	(8,020)


For the six months ended June 30	2020	2021
Reported segment Adjusted EBITDA	3,670	20,195
Corporate expenses	(16,107)	(21,563)
	(12,437)	(1,368)
Share-based payment expenses (Note 11)	(1,393)	(4,276)
Depreciation and amortization	(4,432)	(6,670)
Operating loss	(18,262)	(12,314)
Financial costs, net	(705)	(471)
Income tax expenses	(129)	(124)
Loss for the six months ended June 30	(19,096)	(12,909)

Other income and expenses (Tables)

6 Months Ended

Jun. 30, 2021

Other income and expenses

Schedule of other operating income


	For the Three months ended June 30		For the Six months ended June 30
in EUR k	2020	2021	2020	2021
Government grants	703	837	1,405	1,177
Others	98	439	341	465
Total other operating income	801	1,276	1,746	1,642

Schedule of other operating expenses


	For the Three months ended June 30		For the Six months ended June 30
in EUR k	2020	2021	2020	2021
Currency losses	37	(8)	37	26
Others	—	10	101	10
Total other operating expenses	37	2	138	36

Trade and other receivables and other assets (Tables)

6 Months Ended

Jun. 30, 2021

Trade receivables and other assets

Summary of trade receivables and other assets


in EUR k	Dec 31, 2020	June 30, 2021
Non‑current
Other assets - Rental deposits	1,867	2,923
Other assets – Others	100	100
	1,967	3,023
Current
Trade receivables, net	25,656	15,630
Contract assets, net	3,543	2,860
Other assets	8,286	6,064
	37,485	24,554
Total non-current and current trade receivables and other assets	39,452	27,577

Summary of expected credit loss rate on total gross trade receivables and contract assets


in EUR k	Dec, 2020		June 30, 2021
Not past due	24,185		11,826
Past due 1-30 days	2,228		3,293
Past due 31-90 days	797		2,474
Past due more than 90 days	6,757		6,275
Total gross amount of trade receivables and contract assets	33,967		23,868

Expected credit loss rate
Not past due	1.6	%	1.2	%
Past due 1-30 days	3.1	%	3.6	%
Past due 31-90 days	7.7	%	11.8	%
Past due more than 90 days	63.0	%	77.0	%
Expected credit loss rate on total gross trade receivables and contract assets	14.0	%	22.7	%

Expected credit loss	4,768		5,378

Financial liabilities (Tables)

6 Months Ended

Jun. 30, 2021

Financial liabilities

Schedule of interest-bearing liabilities


in EUR k	Dec 31, 2020	June 30, 2021
Non‑current liabilities
Non‑current portion of secured bank loans	401	200
Total non‑current loans	401	200
Lease liabilities	17,677	16,209
Total non‑current liabilities	18,078	16,409

Current liabilities
Current portion of secured bank loans	567	567
Other bank loans	387	—
Bank overdrafts	1,538	3,316
Total current loans	2,492	3,883
Current portion of lease liabilities	3,528	3,299
Total current liabilities	6,020	7,182

Total non‑current and current liabilities	24,098	23,591

Schedule of outstanding interest-bearing liabilities


				Dec 31, 2020		June 30, 2021
				Nominal	Carrying	Nominal	Carrying
in EUR k	Currency	Nominal interest rate	Maturity	amount	amount	amount	amount
Secured bank loan	EUR	2.95%	2017‑22	968	968	767	767
Other bank loan	USD	1%	2020-22	387	387	—	—
Bank overdrafts	EUR	4.75%	Rollover	498	498	496	496
Bank overdrafts	EUR	3.75%	Rollover	628	628	2,324	2,324
Bank overdrafts	EUR	4.50%	Rollover	412	412	496	496
Lease liabilities	EUR	2.1%-3.5%*, 5.4%-9.1%	2017-31	21,205	21,205	19,508	19,508
Total interest‑bearing financial liabilities				24,098	24,098	23,591	23,591

*	represents the incremental borrowing rate of the Group at the commencement of the leases

Schedule of trade payables and other liabilities


in EUR k	Dec 31, 2020	June 30, 2021
Trade payables	31,736	14,014
Government grants (deferred income)	10,292	9,992
Contract liabilities	4,479	4,913
Others	13,483	10,813
Trade payables and other liabilities	59,990	39,732
Non‑current	8,950	8,640
Current	51,040	31,092

Share-based payments (Tables)

6 Months Ended

Jun. 30, 2021

Share-based payments

Schedule of share option activity


	ESOP 2017		2019-2021 awards ⁽¹⁾
number of awards (options and RSUs)	Number	WAEP	Number of options	WAEP (USD)	Number of RSUs	WAEP
Outstanding as of January 1	549,005	0.12	154,925	11.60	1,885,100	—
Granted during the year(1)	—	0.12	30,152	12.57	150,804	—
Exercised during the year	(140,169)	0.12	—	—	(187,430)	—
Outstanding as of June 30	408,836	0.12	185,077	11.76	1,848,474	—
Vested as of June 30	408,836		111,591		230,992
Exercisable as of June 30	408,836		111,591		230,992

(1)

Summary of Restricted Stock Units


	ESOP 2017		2019-2021 awards ⁽¹⁾
number of awards (options and RSUs)	Number	WAEP	Number of options	WAEP (USD)	Number of RSUs	WAEP
Outstanding as of January 1	549,005	0.12	154,925	11.60	1,885,100	—
Granted during the year(1)	—	0.12	30,152	12.57	150,804	—
Exercised during the year	(140,169)	0.12	—	—	(187,430)	—
Outstanding as of June 30	408,836	0.12	185,077	11.76	1,848,474	—
Vested as of June 30	408,836		111,591		230,992
Exercisable as of June 30	408,836		111,591		230,992

(1)

Summary of awards granted

During the six months ended June 30, 2021 the following awards were granted:


Award Type (2019 Plan)	Market/ Performance Based Vesting Conditions	Number of Awards	Vesting Conditions	Expiration Date
RSUs	No	105,804	Four equal tranches over a four-year period, starting January 1, 2022, April 1, 2022 or on each anniversary of the grant date	10th anniversary of Grant Date
RSUs	No	30,000	Three equal tranches over a three-year period starting January 1, 2022	10th anniversary of Grant Date
RSUs	No	15,000	Three equal tranches of which the first tranche vested immediately and the two remaining annual tranches will vest starting January 1, 2022	10th anniversary of Grant Date
Options	No	15,152	Four equal tranches over a four-year period following each anniversary of the grant date	10th anniversary of Grant Date
Options	Yes	15,000	Three equal tranches over a three-year period starting January 1, 2022	10th anniversary of Grant Date

General company information (Details) - 1 months ended Jul. 31, 2020 - Follow-on Equity Offering - Common shares - Major purchases of assets € / shares in Units, € in Millions	EUR (€) € / shares shares	$ / shares
General company information
Number of common shares issued (in shares)	3,500,000
Public offering price (in dollars per share) \| (per share)	€ 12.71	$ 14.00
Selling shareholders
General company information
Number of common shares issued (in shares)	1,500,000
The Company
General company information
Number of common shares issued (in shares)	2,000,000
Net offering proceeds, after deducting underwriting discounts, commissions and transaction costs \| €	€ 22

Revenues from contracts with customers - Geographical information (Details) - EUR (€) € in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Disclosure of geographical areas
Rendering of services	€ 51,693	€ 9,343	€ 116,446	€ 21,172
Sales of goods	178	376	385	652
Total Revenues from contracts with external customers	51,871	9,719	116,831	21,824
Europe
Disclosure of geographical areas
Total Revenues from contracts with external customers	43,530	3,227	99,014	4,888
Germany
Disclosure of geographical areas
Total Revenues from contracts with external customers	40,380	2,115	92,778	2,207
-Netherlands
Disclosure of geographical areas
Total Revenues from contracts with external customers	1,774		3,544	3
Middle East
Disclosure of geographical areas
Total Revenues from contracts with external customers	3,976	1,834	8,140	6,252
-Saudi Arabia
Disclosure of geographical areas
Total Revenues from contracts with external customers		1,106		4,139
North America
Disclosure of geographical areas
Total Revenues from contracts with external customers	3,585	4,373	8,234	9,496
United States
Disclosure of geographical areas
Total Revenues from contracts with external customers		4,365	8,125	9,339
Latin America
Disclosure of geographical areas
Total Revenues from contracts with external customers	633	219	1,058	965
Asia Pacific
Disclosure of geographical areas
Total Revenues from contracts with external customers	147	66	385	223
Recognized over time
Disclosure of geographical areas
Total Revenues from contracts with external customers	16,496	7,812	38,116	19,641
Recognized at a point in time
Disclosure of geographical areas
Total Revenues from contracts with external customers	35,375	1,907	78,715	2,183
Pharmaceutical
Disclosure of geographical areas
Rendering of services	2,653	3,606	6,046	7,880
Sales of goods	178	334	383	610
Total Revenues from contracts with external customers	2,831	3,940	6,429	8,490
Pharmaceutical \| Europe
Disclosure of geographical areas
Total Revenues from contracts with external customers	49	23	198	67
Pharmaceutical \| Germany
Disclosure of geographical areas
Total Revenues from contracts with external customers		19		38
Pharmaceutical \| Middle East
Disclosure of geographical areas
Total Revenues from contracts with external customers	26	45	55	48
Pharmaceutical \| North America
Disclosure of geographical areas
Total Revenues from contracts with external customers	2,731	3,872	6,136	8,375
Pharmaceutical \| United States
Disclosure of geographical areas
Total Revenues from contracts with external customers		3,872	6,136	8,375
Pharmaceutical \| Latin America
Disclosure of geographical areas
Total Revenues from contracts with external customers	25		40
Pharmaceutical \| Recognized over time
Disclosure of geographical areas
Total Revenues from contracts with external customers	2,653	3,606	6,046	7,880
Pharmaceutical \| Recognized at a point in time
Disclosure of geographical areas
Total Revenues from contracts with external customers	178	334	383	610
Diagnostics
Disclosure of geographical areas
Rendering of services	6,715	3,684	13,098	11,226
Total Revenues from contracts with external customers	6,715	3,684	13,098	11,226
Diagnostics \| Europe
Disclosure of geographical areas
Total Revenues from contracts with external customers	1,320	1,109	2,534	2,713
Diagnostics \| Germany
Disclosure of geographical areas
Total Revenues from contracts with external customers	57	1	110	61
Diagnostics \| -Netherlands
Disclosure of geographical areas
Total Revenues from contracts with external customers	3		5	3
Diagnostics \| Middle East
Disclosure of geographical areas
Total Revenues from contracts with external customers	3,950	1,789	8,085	6,204
Diagnostics \| -Saudi Arabia
Disclosure of geographical areas
Total Revenues from contracts with external customers		1,106		4,139
Diagnostics \| North America
Disclosure of geographical areas
Total Revenues from contracts with external customers	690	501	1,154	1,121
Diagnostics \| United States
Disclosure of geographical areas
Total Revenues from contracts with external customers		493	1,045	964
Diagnostics \| Latin America
Disclosure of geographical areas
Total Revenues from contracts with external customers	608	219	1,018	965
Diagnostics \| Asia Pacific
Disclosure of geographical areas
Total Revenues from contracts with external customers	147	66	307	223
Diagnostics \| Recognized over time
Disclosure of geographical areas
Total Revenues from contracts with external customers	6,715	3,684	13,098	11,226
COVID-19
Disclosure of geographical areas
Rendering of services	42,325	2,053	97,302	2,066
Sales of goods		42	2	42
Total Revenues from contracts with external customers	42,325	2,095	97,304	2,108
COVID-19 \| Europe
Disclosure of geographical areas
Total Revenues from contracts with external customers	42,161	2,095	96,282	2,108
COVID-19 \| Germany
Disclosure of geographical areas
Total Revenues from contracts with external customers	40,323	2,095	92,668	2,108
COVID-19 \| -Netherlands
Disclosure of geographical areas
Total Revenues from contracts with external customers	1,771		3,539
COVID-19 \| North America
Disclosure of geographical areas
Total Revenues from contracts with external customers	164		944
COVID-19 \| United States
Disclosure of geographical areas
Total Revenues from contracts with external customers			944
COVID-19 \| Asia Pacific
Disclosure of geographical areas
Total Revenues from contracts with external customers			78
COVID-19 \| Recognized over time
Disclosure of geographical areas
Total Revenues from contracts with external customers	7,128	522	18,972	535
COVID-19 \| Recognized at a point in time
Disclosure of geographical areas
Total Revenues from contracts with external customers	€ 35,197	€ 1,573	€ 78,332	€ 1,573

Revenue from contracts with customers - Additional Information (Details) € in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021 EUR (€) customer	Jun. 30, 2020 EUR (€)	Jun. 30, 2021 EUR (€) customer	Jun. 30, 2020 EUR (€)
Germany \| Property Plant And Equipment \| COVID-19
Revenue from contracts with customers
Total investments \| €	€ 618	€ 1,873	€ 2,034	€ 1,903
Germany \| Intangible assets \| COVID-19
Revenue from contracts with customers
Total investments \| €	€ 0	€ 527	€ 354	€ 527
Pharmaceutical Partner \| Pharmaceutical
Revenue from contracts with customers
Number of customer in group \| customer	1		1
Revenue contributed as a percentage of Group's total revenues	4.10%	26.20%	4.40%	26.40%
Covid-19 Segment \| COVID-19
Revenue from contracts with customers
Number of customer in group \| customer	2		2
Revenue contributed as a percentage of Group's total revenues		0.00%		0.00%
Covid-19 Partner One \| COVID-19
Revenue from contracts with customers
Revenue contributed as a percentage of Group's total revenues	5.20%		4.70%
Covid-19 Partner Two \| COVID-19
Revenue from contracts with customers
Revenue contributed as a percentage of Group's total revenues	12.90%		15.20%

Segment information - Information by operating segments (Details) - EUR (€) € in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Segment information
Total Revenues from contracts with external customers	€ 51,871	€ 9,719	€ 116,831	€ 21,824
Adjusted EBITDA	(2,066)	(7,420)	(1,368)	(12,437)
Additions to property, plant and equipment and right-of-use assets	726	3,623	2,696	5,027
Additions to intangible assets	763	2,774	2,089	3,965
Other segment information
Depreciation and amortization	3,384	2,348	6,670	4,432
Research and development expenses	4,053	3,119	8,388	5,810
Pharmaceutical
Segment information
Total Revenues from contracts with external customers	2,831	3,940	6,429	8,490
Diagnostics
Segment information
Total Revenues from contracts with external customers	6,715	3,684	13,098	11,226
COVID-19
Segment information
Total Revenues from contracts with external customers	42,325	2,095	97,304	2,108
Operating segment \| Pharmaceutical
Segment information
Total Revenues from contracts with external customers	2,831	3,940	6,429	8,490
Adjusted EBITDA	647	1,799	2,144	4,407
Additions to property, plant and equipment and right-of-use assets	3	301	9	301
Additions to intangible assets	241	1,852	563	2,854
Other segment information
Depreciation and amortization	410	389	824	1,071
Operating segment \| Diagnostics
Segment information
Total Revenues from contracts with external customers	6,715	3,684	13,098	11,226
Adjusted EBITDA	580	(1,636)	1,633	(1,358)
Additions to property, plant and equipment and right-of-use assets		200	234	987
Other segment information
Depreciation and amortization	412	563	818	1,107
Operating segment \| COVID-19
Segment information
Total Revenues from contracts with external customers	42,325	2,095	97,304	2,108
Adjusted EBITDA	6,251	812	16,418	621
Additions to property, plant and equipment and right-of-use assets	618	1,873	2,034	1,903
Additions to intangible assets		527	354	527
Other segment information
Depreciation and amortization	1,069	54	1,996	54
Corporate
Segment information
Adjusted EBITDA	(9,544)	(8,395)	(21,563)	(16,107)
Additions to property, plant and equipment and right-of-use assets	105	1,249	419	1,836
Additions to intangible assets	522	395	1,172	584
Other segment information
Depreciation and amortization	1,493	1,342	3,032	2,200
Research and development expenses	€ 4,053	€ 3,119	€ 8,388	€ 5,810

Segment information - Reconciliation of segment Adjusted EBITDA to Group Loss for the Period (Details) - EUR (€) € in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Segment information
Depreciation and amortization	€ (3,384)	€ (2,348)	€ (6,670)	€ (4,432)
Operating loss	(7,684)	(10,104)	(12,314)	(18,262)
Financial costs, net	(212)	(256)	(471)	(705)
Income tax expenses	(124)		(124)	(129)
Loss for the period	(8,020)	(10,360)	(12,909)	(19,096)
Operating segment
Segment information
Reportable segment Adjusted EBITDA	7,477	975	20,195	3,670
Reportable segment Adjusted EBITDA after corporate expenses	(2,066)	(7,420)	(1,368)	(12,437)
Operating loss	(7,684)	(10,104)	(12,314)	(18,262)
Financial costs, net	(212)	(256)	(471)	(705)
Income tax expenses	(124)		(124)	(129)
Loss for the period	(8,020)	(10,360)	(12,909)	(19,096)
Corporate
Segment information
Corporate expenses	(9,543)	(8,395)	(21,563)	(16,107)
Depreciation and amortization	(1,493)	(1,342)	(3,032)	(2,200)
Sharebased payment expenses
Segment information
Share-based compensation	(2,234)	(336)	(4,276)	(1,393)
Depreciation and amortization
Segment information
Depreciation and amortization	€ (3,384)	€ (2,348)	€ (6,670)	€ (4,432)

Segment information - Additional information (Details) - EUR (€) € in Thousands	Jun. 30, 2021	Dec. 31, 2020
Segment information
Property, plant and equipment	€ 16,411	€ 16,590
Right-of-use assets.	20,558	22,120
United States
Segment information
Property, plant and equipment	460	516
Right-of-use assets.	€ 449	€ 709

Other income and expenses - Other operating income (Details) - EUR (€) € in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Other income and expenses
Government grants	€ 837	€ 703	€ 1,177	€ 1,405
Others	439	98	465	341
Total other operating income	€ 1,276	€ 801	€ 1,642	€ 1,746

Other income and expenses - Other operating expenses (Details) - EUR (€) € in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Other income and expenses
Currency losses	€ (8)	€ 37	€ 26	€ 37
Other	10		10	101
Total other operating expenses	€ 2	€ 37	€ 36	€ 138

Other income and expenses - LPC GmbH (Details) - EUR (€) € in Thousands	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2021	Dec. 31, 2020
Other income and expenses
Noncontrolling interests		€ 141	€ 95
LPC GmbH
Other income and expenses
Proportion of ownership interest in subsidiary	51.00%
Consideration for disposal of subsidiary	€ 213
Consideration to be received over time	€ 200
Payment due period (in years)	4 years
Noncontrolling interests	€ (268)
Profit/(loss) allocated to non-controlling interest	€ (101)

Trade receivables and other assets (Details) - EUR (€) € in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020
Non-current
Other assets-Rental deposits	€ 2,923		€ 2,923		€ 1,867
Other assets-Others	100		100		100
Trade receivables and contract assets and other assets non-current	3,023		3,023		1,967
Current
Trade receivables, net	15,630		15,630		25,656
Contract assets, net	2,860		2,860		3,543
Other assets	6,064		6,064		8,286
Trade receivables and contract assets and other assets current	24,554		24,554		37,485
Total non-current and current trade receivables and contract assets and other assets	27,577		27,577		39,452
Credit loss rates in relation to the outstanding trade receivables and contract assets
Impairment of financial assets	580	€ 500	675	€ 1,674
Trade receivables and contract assets
Credit loss rates in relation to the outstanding trade receivables and contract assets
Financial assets	€ 23,868		€ 23,868		€ 33,967
Expected credit loss rate	22.70%		22.70%		14.00%
Expected credit loss	€ 5,378		€ 5,378		€ 4,768
Trade receivables and contract assets \| Not past due
Credit loss rates in relation to the outstanding trade receivables and contract assets
Financial assets	€ 11,826		€ 11,826		€ 24,185
Expected credit loss rate	1.20%		1.20%		1.60%
Trade receivables and contract assets \| Past due 1-30 days
Credit loss rates in relation to the outstanding trade receivables and contract assets
Financial assets	€ 3,293		€ 3,293		€ 2,228
Expected credit loss rate	3.60%		3.60%		3.10%
Trade receivables and contract assets \| Past due 31-90 days
Credit loss rates in relation to the outstanding trade receivables and contract assets
Financial assets	€ 2,474		€ 2,474		€ 797
Expected credit loss rate	11.80%		11.80%		7.70%
Trade receivables and contract assets \| Past due more than 90 days
Credit loss rates in relation to the outstanding trade receivables and contract assets
Financial assets	€ 6,275		€ 6,275		€ 6,757
Expected credit loss rate	77.00%		77.00%		63.00%
Minimum
Current
Receivables payment terms			30 days
Maximum
Current
Receivables payment terms			90 days
Other assets
Credit loss rates in relation to the outstanding trade receivables and contract assets
Current value added tax receivables	€ 0		€ 0		€ 226
Prepaid expenses	2,873		2,873		4,431
Receivables from exercise of share based payments granted	283		283		1,253
Receivables from COVID 19 bank or credit card transactions	435		435		1,076
Receivables from grants	1,280		1,280		€ 442
Other assets \| Rostock headquarters building
Credit loss rates in relation to the outstanding trade receivables and contract assets
Cash deposits provided as security for bank loans	2,250		2,250
Bank guarantee	3,000		3,000
Other assets \| Berlin Offices
Credit loss rates in relation to the outstanding trade receivables and contract assets
Cash deposits provided as security for bank loans	192		192
Bank guarantee	257		257
Other assets \| Plant and other equipment, furniture and fixtures Certain plant and machineries
Non-current
Other assets-Rental deposits	285		285
Other assets \| LPC GmbH
Credit loss rates in relation to the outstanding trade receivables and contract assets
Consideration receivable for the sale of LPC	€ 100		€ 100

Cash and short-term deposits (Details) - EUR (€) € in Thousands	Jun. 30, 2021	Dec. 31, 2020
Secured bank loan
Borrowings
Short term deposits pledged as security	€ 1,500	€ 1,500
Overdraft facility
Borrowings
Short term deposits pledged as security	1,000	1,000
Existing Overdraft facility
Borrowings
Short term deposits pledged as security	2,500	€ 2,500
Maximum borrowing capacity	2,500
Second Overdraft facility
Borrowings
Maximum borrowing capacity	€ 500

Equity - Common Shares (Details) - Common shares - EUR (€) € / shares in Units, € in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Disclosure of classes of share capital [line items]
Number of shares issued and fully paid	22,445,242	22,117,643
Par value per share (in euros per share)	€ 0.12
Authorized but unissued share capital	€ 6,787	€ 6,826

Equity - Capital Reserves (Details) - EUR (€) € in Thousands	Jun. 30, 2021	Dec. 31, 2020
Capital reserve
Share premium included in capital reserve	€ 107,459	€ 107,498

Financial liabilities - Interest-bearing loans (Details) - EUR (€) € in Thousands	Jun. 30, 2021	Dec. 31, 2020
Financial liabilities
Total non-current liabilities	€ 16,409	€ 18,078
Total current liabilities	7,182	6,020
Total non-current and current liabilities	23,591	24,098
Total loans
Financial liabilities
Total non-current liabilities	200	401
Total current liabilities	3,883	2,492
Secured bank loans
Financial liabilities
Total non-current liabilities	200	401
Total current liabilities	567	567
Short term deposits pledged as security	1,500	1,500
Other bank loans
Financial liabilities
Total current liabilities		387
Total non-current and current liabilities		387
Bank overdrafts
Financial liabilities
Total current liabilities	3,316	1,538
Lease liabilities
Financial liabilities
Total non-current liabilities	16,209	17,677
Total current liabilities	3,299	3,528
Total non-current and current liabilities	€ 19,508	€ 21,205

Financial liabilities - Conditions and statement of liabilities (Details) - EUR (€) € in Thousands	Jun. 30, 2021	Dec. 31, 2020
Financial liabilities
Nominal amount	€ 23,591	€ 24,098
Carrying amount	23,591	24,098
Bank overdrafts	992	910
Secured bank loans
Financial liabilities
Financial assets pledged as collateral for liabilities or contingent liabilities	€ 1,500	€ 1,500
Secured Bank Loans With Maturity Period 2017 To 22
Financial liabilities
Nominal interest rate (as a percent)	2.95%	2.95%
Nominal amount	€ 767	€ 968
Carrying amount	€ 767	€ 968
Other bank loans
Financial liabilities
Nominal interest rate (as a percent)	1.00%	1.00%
Nominal amount		€ 387
Carrying amount		€ 387
Bank overdrafts, one
Financial liabilities
Nominal interest rate (as a percent)	4.75%	4.75%
Nominal amount	€ 496	€ 498
Carrying amount	€ 496	€ 498
Bank overdrafts, two
Financial liabilities
Nominal interest rate (as a percent)	3.75%	3.75%
Nominal amount	€ 2,324	€ 628
Carrying amount	€ 2,324	€ 628
Bank overdrafts, three
Financial liabilities
Nominal interest rate (as a percent)	4.50%	4.50%
Nominal amount	€ 496	€ 412
Carrying amount	496	412
Lease liabilities
Financial liabilities
Nominal amount	19,508	21,205
Carrying amount	€ 19,508	€ 21,205
Minimum \| Lease liabilities
Financial liabilities
Nominal interest rate (as a percent)	5.40%	5.40%
Nominal interest rate at commencement of leases	2.10%	2.10%
Maximum \| Lease liabilities
Financial liabilities
Nominal interest rate (as a percent)	9.10%	9.10%
Nominal interest rate at commencement of leases	3.50%	3.50%
Overdraft facility
Financial liabilities
Financial assets pledged as collateral for liabilities or contingent liabilities	€ 1,000	€ 1,000
Short-term deposits, pledged as security	2,500	2,500
Existing Overdraft facility
Financial liabilities
Financial assets pledged as collateral for liabilities or contingent liabilities	2,500	€ 2,500
Second Overdraft facility
Financial liabilities
Short-term deposits, pledged as security	€ 500

Financial liabilities - Trade payables and other liabilities (Details) - EUR (€) € in Thousands	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020
Disclosure of reconciliation of liabilities arising from financing activities
Trade payables	€ 14,014		€ 31,736
Government grants (deferred income)	9,992		10,292
Contract liabilities	4,913		4,479
Others	10,813		13,483
Trade payables and other liabilities	39,732		59,990
Non-current	8,640		8,950
Current	31,092		51,040
Grants received for investment in property, plant and equipment	0	€ 390
Provision for outstanding invoices	4,931		1,245
Personnel related liabilities for vacation and bonuses	3,245		4,032
VAT payable	119		4,578
Liabilities for wage and church tax	€ 920		€ 1,988

Share-based payments - Expenses from share-based payment arrangements (Details) - EUR (€) € in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Expenses arising from share-based payment transactions
Share-based payment expenses	€ 2,234	€ 336	€ 4,276	€ 1,393

Share-based payments - Share-based award activity (Details)	6 Months Ended
	Jun. 30, 2021 USD ($) € / shares shares	Jun. 30, 2021 USD ($) $ / shares shares
Options
Number
Granted during the year	75,000	75,000
Equity share option 2017 (Equity settled)
Share-based payments
Exercise price of share options granted \| € / shares	€ 0.12
Number
Outstanding at January 1	549,005	549,005
Exercised during the year	(140,169)	(140,169)
Outstanding as of June 30	408,836	408,836
Vested as of June 30 \| shares	408,836	408,836
Exercisable as of June 30	408,836	408,836
WAEP
Outstanding as of January 1 \| € / shares	€ 0.12
Granted during the year \| € / shares	0.12
Exercised during the year \| (per share)	0.12	$ 11.67
Outstanding as of June 30 \| € / shares	€ 0.12
2019 Plan \| Options
Share-based payments
Exercise price of share options granted \| $ / shares		$ 12.57
Number
Outstanding at January 1	154,925	154,925
Granted during the year	30,152	30,152
Outstanding as of June 30	185,077	185,077
Vested as of June 30 \| shares	111,591	111,591
Exercisable as of June 30	111,591	111,591
WAEP
Outstanding as of January 1 \| $ / shares		$ 11.60
Granted during the year \| $ / shares		12.57
Outstanding as of June 30 \| $ / shares		$ 11.76
2019 Plan \| RSUs
Number
Outstanding as of January 1	1,885,100	1,885,100
Granted during the year	150,804	150,804
Exercised during the year	(187,430)	(187,430)
Outstanding as of June 30	1,848,474	1,848,474
Vested as of June 30 \| shares	230,992	230,992
Exercisable as of June 30	230,992	230,992
WAEP
Exercised during the year \| $ / shares		$ 11.74

Share-based payments - Management board and employees Options and RSUs grants awarded and exercises (Details)		3 Months Ended	6 Months Ended
	Dec. 01, 2020 Options	Jun. 30, 2021 USD ($) $ / shares shares	Jun. 30, 2021 USD ($) € / shares shares	Jun. 30, 2021 USD ($) tranche $ / shares shares
Chief Executive Officer
Disclosure of terms and conditions of share-based payment arrangement [line items]
RSUs granted \| Options	324,000
Options
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of options granted				75,000
Trading days				20 days
Exercise price \| $ / shares				$ 11.60
Incremental fair value				$ 226,000
2019 Plan
Disclosure of terms and conditions of share-based payment arrangement [line items]
Expiration Date				10 years
Weighted average fair value of RSUs granted \| $ / shares		$ 10.17		$ 10.91
Weighted average fair value of share options granted \| $ / shares		$ 7.59		$ 7.47
2019 Plan \| RSUs
Disclosure of terms and conditions of share-based payment arrangement [line items]
RSUs granted				150,804
RSUs vested and are exercisable		230,992	230,992	230,992
No of RSUs exercised during the period				187,430
Weighted average share price of RSUs exercised during the period \| $ / shares				$ 11.74
2019 Plan \| Options
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of options granted				30,152
Trading days				20 days
Exercise price \| $ / shares				$ 12.52
No of options vested during the period \| shares		111,591	111,591	111,591
2019 Plan \| Options \| Vesting in three tranches
Disclosure of terms and conditions of share-based payment arrangement [line items]
No of options vested during the period \| shares		15,000	15,000	15,000
Equity share option 2017 (Equity settled)
Disclosure of terms and conditions of share-based payment arrangement [line items]
No of options vested during the period \| shares		408,836	408,836	408,836
No of options exercised during the period				140,169
Weighted average share price of options exercised during the period \| (per share)			€ 0.12	$ 11.67
RSU Granted One
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of Awards				105,804
Number of tranches \| tranche				4
Vesting period				4 years
Expiration Date				10 years
RSU Granted Two
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of Awards				30,000
Number of tranches \| tranche				3
Vesting period				3 years
Expiration Date				10 years
RSU Granted Three
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of Awards				15,000
Number of tranches \| tranche				3
Expiration Date				10 years
Options Granted One
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of Awards				15,152
Number of tranches \| tranche				4
Vesting period				4 years
Expiration Date				10 years
Options Granted Two
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of Awards				15,000
Number of tranches \| tranche				3
Vesting period				3 years
Expiration Date				10 years

Commitments (Details) - EUR (€) € in Thousands	6 Months Ended	12 Months Ended
Commitments (Details) - EUR (€) € in Thousands	Jun. 30, 2021	Dec. 31, 2020
Lease commitments
Total payment obligation	€ 2,857	€ 4,669
Rostock headquarters building \| Within one year
Lease commitments
Future lease payments to be made	1,667	283
Rostock headquarters building \| Within five years
Lease commitments
Future lease payments to be made	2,424	1,686
Rostock headquarters building \| Later than 5 years
Lease commitments
Future lease payments to be made	4,219	4,855
Office equipment and storage spaces \| Within one year
Lease commitments
Future lease payments to be made	16	33
Office equipment and storage spaces \| Within five years
Lease commitments
Future lease payments to be made	€ 2	€ 9

Contingent Liabilities (Details) - EUR (€) € in Thousands	6 Months Ended
Contingent Liabilities (Details) - EUR (€) € in Thousands	Jun. 30, 2021	Nov. 08, 2018
Universitair Medisch Centrum Utrecht
Contingent Liabilities
Disputed amount	€ 1,300	€ 880
State of Mecklenburg-Western Pomerania ("MVP")
Contingent Liabilities
Disputed amount	2,300
Amounts received on invoices	€ 2,300

Subsequent Events (Details)		3 Months Ended	6 Months Ended
Subsequent Events (Details)	Dec. 01, 2020 CHF (SFr) Options	Sep. 30, 2021 Options tranche	Jun. 30, 2021 USD ($)	Aug. 07, 2021 EUR (€)
Chief Executive Officer
Subsequent Event
RSUs granted	324,000
RSUs \| Chief Executive Officer
Subsequent Event
Required investment in ordinary shares \| SFr	SFr 1,000,000
2019 Plan \| RSUs
Subsequent Event
RSUs granted \| $			150,804
Grant of RSUs \| 2019 Plan \| RSUs \| Management
Subsequent Event
RSUs granted		22,936
Vesting period		4 years
Grant of RSUs \| 2019 Plan \| Vesting in four tranches \| RSUs \| Management
Subsequent Event
Number of tranches \| tranche		4
Association Of Statutory Health Insurance Physicians \| Prof. Dr. Peter Bauer
Subsequent Event
Disputed amount \| €				€ 42,268.50